1. Home
  2. |Professionals
  3. |Judy He

Judy He

Counsel | She/Her/Hers
Counsel | She/Her/Hers
amhlQGNyb3dlbGwuY29t
VCardLinkedIn
VCardLinkedIn

Areas of Focus

Overview

Judy is a patent and trade secrets litigator who is committed to helping her clients resolve complex global IP disputes by developing and implementing smart, cost-effective strategies that address both legal and business needs. Judy has represented companies across various industries, including pharmaceuticals, medical devices, vaping devices, and more, from pre-suit to post-trial and appeal before federal courts. Judy also has experience with petitions before the Patent Trial and Appeal Board (PTAB) and investigations before International Trade Commission (ITC). In 2024, Judy was one of the recipients of the American Bar Association’s “On the Rise” Award, which recognizes young lawyers who exemplify a broad range of high achievement, innovation, vision, leadership, and legal and community service.

Judy also has an active pro bono practice. In 2021, Judy was a recipient of the National Immigrant Justice Center’s Rising Star Award, and she was recognized twice by the American Bar Association Standing Committee on Pro Bono and Public Service as a Pro Bono Leader for her contributions in 2020 and 2021 to the ABA’s Free Legal Answers project. Prior to becoming a lawyer, Judy was an extern with the U.S. Immigration and Customs Enforcement Office of the Principal Legal Advisor, the largest legal program in the Department of Homeland Security, and she was a Public Interest Law Initiative Fellow at the Young Center for Immigrant Children’s Rights.

Outside of the firm, Judy is a coffee lover, and she enjoys running and reading fiction.

Career & Education

    • Department of Homeland Security
      Extern, Office of the Principal Legal Advisor, U.S. Immigration and Customs Enforcement, 2016
    • Department of Homeland Security
      Extern, Office of the Principal Legal Advisor, U.S. Immigration and Customs Enforcement, 2016

    • PILI Fellow at the Young Center for Immigrant Children’s Rights, 2017
    • Managing Editor of Iowa Law Review, Volume 102, 2016–2017
    • Judicial Intern to the Honorable Linnea E. Thompson in the Fourteenth Judicial Circuit of Illinois, 2015
    • Loyola University Chicago School of Law, Chicago, IL
      Adjunct Professor, Legal Writing I and II, 2022-2024
    • PILI Fellow at the Young Center for Immigrant Children’s Rights, 2017
    • Managing Editor of Iowa Law Review, Volume 102, 2016–2017
    • Judicial Intern to the Honorable Linnea E. Thompson in the Fourteenth Judicial Circuit of Illinois, 2015
    • Loyola University Chicago School of Law, Chicago, IL
      Adjunct Professor, Legal Writing I and II, 2022-2024

    • University of Iowa, B.A., With Honors, Chemistry, 2014
    • University of Iowa, B.B.A., With Honors, Finance, 2014
    • University of Iowa College of Law, J.D., 2017
    • University of Iowa, B.A., With Honors, Chemistry, 2014
    • University of Iowa, B.B.A., With Honors, Finance, 2014
    • University of Iowa College of Law, J.D., 2017

    • Illinois
    • U.S. Patent and Trademark Office (USPTO)
    • U.S. District Court for the Northern District of Illinois
    • U.S. Court of Appeals for the Federal Circuit
    • Supreme Court of the United States
    • U.S. Court of Appeals for the Fifth Circuit
    • U.S. Court of Appeals for the Fourth Circuit
    • Illinois
    • U.S. Patent and Trademark Office (USPTO)
    • U.S. District Court for the Northern District of Illinois
    • U.S. Court of Appeals for the Federal Circuit
    • Supreme Court of the United States
    • U.S. Court of Appeals for the Fifth Circuit
    • U.S. Court of Appeals for the Fourth Circuit

  • Professional Activities and Memberships

    • Intellectual Property Law Association of Chicago (IPLAC)
      • Board Member (2024–2025)
      • Board Member and Sponsorship Chair (2023–2024)
      • Board Member and Programming Chair (2022–2023)
    • Intellectual Property Owners Association (IPO)
      • Vice Chair of U.S. Patent and Litigation Committee (2024)
      • Secretary of Patent Litigation & Remedies Committee (2023)
    • Red Shoe Society Chicago (RSS)
      • Chair of Communications Committee (2024)
    • Public Interest Law Initiative (PILI), Young Professionals Board
      • Immediate Chair (2023–2024)
      • Chair (2022–2023)
      • Chair–Elect (2021–2022)
      • Vice Chair and Membership Chair (2020–2021)
    • Chicago Women in IP (ChiWIP)
      • DEI Steering Group (2023 to 2025)
      • Member of Annual Events Committee (2024-2025)
      • Co–Chair of Community Involvement Committee (2023–2024)
    • Women In Bio (WIB)
      • National Membership Chair (2021–2023)
    • National Immigrant Justice Center (NIJC)
      • Associate Leadership Board Member (2023–Present)
    • ABA Section of Litigation Judicial Intern Opportunity Program (JIOP)
      • Regional Co-Chair – Illinois (2024 to Present)
      • Illinois Working Group Member (2021–2024)
    • Leadership Council on Legal Diversity (LCLD)
      • Class Liaison for 2022 Pathfinders (2022–Present)

    Professional Activities and Memberships

    • Intellectual Property Law Association of Chicago (IPLAC)
      • Board Member (2024–2025)
      • Board Member and Sponsorship Chair (2023–2024)
      • Board Member and Programming Chair (2022–2023)
    • Intellectual Property Owners Association (IPO)
      • Vice Chair of U.S. Patent and Litigation Committee (2024)
      • Secretary of Patent Litigation & Remedies Committee (2023)
    • Red Shoe Society Chicago (RSS)
      • Chair of Communications Committee (2024)
    • Public Interest Law Initiative (PILI), Young Professionals Board
      • Immediate Chair (2023–2024)
      • Chair (2022–2023)
      • Chair–Elect (2021–2022)
      • Vice Chair and Membership Chair (2020–2021)
    • Chicago Women in IP (ChiWIP)
      • DEI Steering Group (2023 to 2025)
      • Member of Annual Events Committee (2024-2025)
      • Co–Chair of Community Involvement Committee (2023–2024)
    • Women In Bio (WIB)
      • National Membership Chair (2021–2023)
    • National Immigrant Justice Center (NIJC)
      • Associate Leadership Board Member (2023–Present)
    • ABA Section of Litigation Judicial Intern Opportunity Program (JIOP)
      • Regional Co-Chair – Illinois (2024 to Present)
      • Illinois Working Group Member (2021–2024)
    • Leadership Council on Legal Diversity (LCLD)
      • Class Liaison for 2022 Pathfinders (2022–Present)

    • Mandarin
    • Mandarin

Judy's Insights

Client Alert | 4 min read | 05.05.26

Are Skinny Labels Getting Heavier for Generics? Key Takeaways from Hikma v. Amarin, the Supreme Court's First Patent Case Since 2023

As prescription drug prices continue to soar in the United States, the Supreme Court recently heard the highly anticipated oral arguments in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., the first patent case at the Court since 2023. While the Justices did not seem motivated to make significant changes to the current standards for induced patent infringement, the stakes are high for brand and generic pharmaceutical companies, as each side continues to wrestle with the main dilemma that this case raises: What is the right balance between marketing skinny labels to engage in lawful generic competition and avoiding induced infringement liability?...

View All Insights

Recognition

  • American Bar Association, On the Rise – Top 40 Young Lawyers, 2024
  • Super Lawyers, Illinois Rising Star for Intellectual Property Litigation, 2023–2025
  • NITA: Master Advocate, 2022; Advocate, 2018
  • ABA Free Legal Answers: Pro Bono Leader, 2021 and 2022
  • National Immigrant Justice Center: Rising Star, 2021
  • ABA-Bloomberg BNA: Award for Excellence in the Study of Intellectual Property Law, 2017
  • Boyd Service Award, Highest Honors, 2017

Judy's Insights

Client Alert | 4 min read | 05.05.26

Are Skinny Labels Getting Heavier for Generics? Key Takeaways from Hikma v. Amarin, the Supreme Court's First Patent Case Since 2023

As prescription drug prices continue to soar in the United States, the Supreme Court recently heard the highly anticipated oral arguments in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., the first patent case at the Court since 2023. While the Justices did not seem motivated to make significant changes to the current standards for induced patent infringement, the stakes are high for brand and generic pharmaceutical companies, as each side continues to wrestle with the main dilemma that this case raises: What is the right balance between marketing skinny labels to engage in lawful generic competition and avoiding induced infringement liability?...

View All Insights

Insights

Client Alert | 4 min read | 05.05.26

Are Skinny Labels Getting Heavier for Generics? Key Takeaways from Hikma v. Amarin, the Supreme Court's First Patent Case Since 2023

Firm News | 1 min read | 12.11.25

Judy He Honored with Public Interest Law Initiative’s Fellow Alumni Award

Firm News | 1 min read | 07.09.25

Tahirih Justice Center Honors Crowell & Moring with Pro Bono Team of the Year Recognition

Publication | July-August 2025

First Impressions Matter: Federal Circuit Holds That Patents Claiming Application of Generic Machine Learning to New Data Environments Are Not Patent Eligible

View All Insights

Practices

Industries

Judy's Insights

Client Alert | 4 min read | 05.05.26

Are Skinny Labels Getting Heavier for Generics? Key Takeaways from Hikma v. Amarin, the Supreme Court's First Patent Case Since 2023

As prescription drug prices continue to soar in the United States, the Supreme Court recently heard the highly anticipated oral arguments in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., the first patent case at the Court since 2023. While the Justices did not seem motivated to make significant changes to the current standards for induced patent infringement, the stakes are high for brand and generic pharmaceutical companies, as each side continues to wrestle with the main dilemma that this case raises: What is the right balance between marketing skinny labels to engage in lawful generic competition and avoiding induced infringement liability?...

View All Insights